Corona: Next industry giant starts study with Omicron vaccine
Created: 01/27/2022, 09:20 am
The vaccine manufacturer Moderna is now also testing its vaccine adapted to the omicron variant.
© Eugene Hoshiko/dpa/AP
After Biontech and Pfizer announced their first studies on an adapted omicron vaccine, Moderna is now following suit.
Bangalore - After Biontech and Pfizer, the US biotech group Moderna has also started a first clinical study with a corona vaccine adapted to the omicron virus variant.
The vaccine is to be tested on adults over the age of 18, Moderna said.
This is to verify the effectiveness of the adapted vaccine as both a third and fourth dose.
Moderna: Omicron vaccine is tested on 300 subjects
It is being tested in two groups: adults who have received two doses of the current Moderna vaccine and adults who have also received a booster dose of the existing Moderna vaccine.
Around 300 test persons should take part in each of the two groups.
The study is planned to take place at up to 24 locations in the United States.
The omicron variant is currently responsible for almost all corona* infections in the USA.
The company also reported on Wednesday about the results of the effectiveness * of the already approved booster vaccine that was not specially adapted to Omikron against the new variant.
According to this, the number of antibodies fell to one sixth of the maximum value six months after the booster vaccination.
The data were based on studies of 20 subjects who received a half dose of the first two booster doses.
It was "reassuring" that the antibodies were still detectable six months after the booster, said Moderna CEO Stephane Bancel.
Corona: Existing vaccines not effective enough against omicron
The background to the development is that the existing Covid-19 vaccines against Omikron are significantly less effective.
However, three doses of the Moderna vaccine were able to neutralize the variant.
But the vaccination protection with Omikron decreases faster after the booster vaccination than with the original Corona variant.
(rtr/AFP) *Merkur.de is an offer from IPPEN.MEDIA.